Genetic Testing for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the frequency of specific genetic mutations, particularly BRCA1 and BRCA2, in individuals of Ashkenazi Jewish descent with pancreatic cancer. Understanding these mutations can aid in early screening and treatment for at-risk family members. Individuals diagnosed with pancreatic cancer and of Ashkenazi Jewish descent may be suitable candidates for this study.
As an unphased trial, this study provides a unique opportunity to contribute to significant genetic research that could benefit future generations.
Why are researchers excited about this trial?
Researchers are excited about the Pancreatic Cancer Genetics trial because it aims to uncover the genetic factors that contribute to pancreatic cancer, potentially revolutionizing how we understand and treat the disease. Unlike traditional treatments like chemotherapy and radiation, which broadly target cancer cells, this trial focuses on identifying specific genetic mutations that could lead to more personalized and effective treatment strategies. By understanding the genetic landscape of pancreatic cancer, researchers hope to develop targeted therapies that can improve survival rates and reduce side effects by honing in on the unique genetic makeup of a patient's tumor.
Who Is on the Research Team?
Fay Kastrinos, MD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Genetic Testing
Participants undergo genetic testing to determine the frequency of BRCA1 and BRCA2 mutations
Follow-up
Participants are monitored for safety and effectiveness after genetic testing
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor